Sparsentan (PS-433540,RE-021,DARA)
CAS : 254740-64-2
Ref. 3D-EKA74064
1mg | Arrêté | ||
5mg | Arrêté | ||
10mg | Arrêté | ||
25mg | Arrêté | ||
50mg | Arrêté |
Informations sur le produit
Sparsentan is an investigational drug that acts as a selective, orally available, small-molecule inhibitor of the enzyme TGR5. It has been shown to have efficacy in animal models for metabolic disorders and infectious diseases such as atherosclerotic cardiovascular disease, cerebrotendinous xanthomatosis, monoclonal antibody-associated glomerulonephritis, diabetic neuropathy, and ldl-c lowering. Sparsentan is currently undergoing phase 2 clinical trials for type II diabetes mellitus.